Biopharma News & Analysis

Craig-Hallum Raises Celcuity Stock Price Target to $141 Following NDA Progress

Craig-Hallum increased its price target for Celcuity to $141 due to advancements in their New Drug Application (NDA). This change reflects the firm’s confidence in the company's developments. The updated target may impact investor sentiment and trading strategies in the biopharmaceutical sector. Celcuity's stock performance and market positioning could be positively influenced by this revision.